- Home
- ADPT vs NVG Comparison
ADPT vs NVG Comparison
Compare ADPT & NVG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ADPT | NVG |
|---|---|---|
| Founded | 2009 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.9B |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | ADPT | NVG |
|---|---|---|
| Price | $14.91 | $12.86 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $17.78 | N/A |
| AVG Volume (30 Days) | ★ 1.6M | 768.2K |
| Earning Date | 05-05-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 4.65% |
| EPS Growth | ★ 63.89 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $276,976,000.00 | N/A |
| Revenue This Year | $3.98 | N/A |
| Revenue Next Year | $22.72 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 54.77 | N/A |
| 52 Week Low | $6.26 | $11.00 |
| 52 Week High | $20.76 | $13.59 |
Technical Indicators
Market Signals| Indicator | ADPT | NVG |
|---|---|---|
| Relative Strength Index (RSI) | 36.46 | 36.63 |
| Support Level | $12.32 | $12.38 |
| Resistance Level | $17.91 | $12.93 |
| Average True Range (ATR) | 0.74 | 0.13 |
| MACD | -0.01 | -0.07 |
| Stochastic Oscillator | 3.89 | 12.31 |
Price Performance
Historical ComparisonAbout ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
About NVG Nuveen AMT-Free Municipal Credit Income Fund
Nuveen AMT-Free Municipal Credit Income Fund is a diversified, closed-end management investment company. Its objective is to provide current income exempt from regular federal income tax and federal alternative minimum tax applicable to individuals and enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the investment adviser believes are underrated or undervalued or represent undervalued municipal market sectors.